EXC 2049:  NeuroCure

• Subject Area: Neurosciences ; Basic Research in Biology and Medicine ; Medicine
• Term: since 2019
• Website: Homepage
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 390688087

Neurological and psychiatric disorders pose a massive burden to society, and our understanding of the underlying molecular and pathophysiological mechanisms is limited. In addition, translation of knowledge into clinical advances has proven difficult. Learning from achievements and challenges met in the past, NeuroCure is now proposing an innovative research agenda bringing together 25 excellent scientists with state-of-the-art expertise in selected research areas that have the potential to transform basic and translational neuroscience. Our goal is to narrow the current gap between basic and clinical neuroscience and thereby promote the development of successful therapies and diagnostic tools. We will provide tailored programs and create structures designed to support collaboration and facilitate exchange of expertise and methodologies between basic researchers and clinicians. Our focus is not restricted to a specific brain disease; rather, our overarching aim is to elucidate the overlapping pathophysiological processes that are common across multiple neurological and psychiatric disorders. With this proposal we are now focusing on collaborative projects in three areas of neuroscience research: development, maintenance, and aging. These research areas will be flanked by newly established translational modules: BrainLab will provide researchers with increased patient access, including access to inpatients with acute and severe brain disorders; SPARK aims to accelerate and improve the translational process; VOS strengthens the predictive power of our research and thereby improves the translational pipeline. With the integration of new researchers into the highly collaborative NeuroCure research environment, supplemented by the generation of new programs and structures designed specifically to facilitate the application of relevant advances to the clinical setting, we hope to lead our research towards the forefront in translational neuroscience.

• DFG Programme: Clusters of Excellence (ExStra)
• Applicant Institution: Charité - Universitätsmedizin Berlin
• Co-Applicant Institution: Freie Universität Berlin; Humboldt-Universität zu Berlin
• Participating Institution: Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP); im Forschungsverbund Berlin e.V.; Max-Delbrück-Centrum für Molekulare Medizin (MDC); Max-Planck-Forschungsstelle für die Wissenschaft der Pathogene; Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE); c/o Charité - Universitätsmedizin Berlin
• Spokespersons: Professor Dr. Ulrich Dirnagl, until 12/2019; Professor Dr. Dietmar Schmitz
• Participating Researchers: Professorin Dr. Carmen Birchmeier; Professor Dr. Michael Brecht; Professorin Dr. Emmanuelle Charpentier, Ph.D.; Professorin Dr. Isabel Dziobek; Professor Dr. Matthias Endres; Professor Dr. Craig C. Garner; Professor Volker Haucke, Ph.D.; Professor Dr. Peter Hegemann; Professorin Dr. Christine Heim, Ph.D.; Professor Dr. Andreas Heinz; Professor Dr. Frank Heppner; Professor Dr. Thomas J. Jentsch; Professor Dr. Benjamin Judkewitz, Ph.D.; Professorin Dr. Andrea Kühn; Professor Matthew Larkum; Professor Dr. David Owald; Professor Dr. Andrew Plested; Professorin Dr. Ana Pombo, Ph.D.; Professor Dr. Nikolaus Rajewsky; Professor Dr. Christian Rosenmund; Professor Dr. Markus Schülke-Gerstenfeld; Professor Dr. Stephan J. Sigrist; Dr. Daniela Vallentin